BRAF and neoplasm: PF-07284892, an allosteric SHP2 inhibitor, combined with encorafenib and binimetinib, overcame bypass-signaling-mediated resistance in various tumor models, including BRAF V600E-mutant colorectal cancer, presenting a valuable model for testing novel drug combinations [98].